New Peer Review Article Entitled "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia" Published in Therapeutic Advances in Urology

Stock Information for Nymox Pharmaceutical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nymox Pharmaceutical Corporation

Nymox Delisting from NASDAQ
Nymox Provides Current Update
Nymox Provides Corporate Update
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
Nymox Officially Granted Extension to Regain Listing Requirements
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
NYMOX Appeals Deficiency Letter
NYMOX Announces New Marketing Submission for NYMOZARFEX(TM) for BPH

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.